Cost-effectiveness of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis in Belarus, Georgia, Kazakhstan and the Republic of Moldova

IntroductionPrior to 2020, treatment options for multidrug-resistant tuberculosis (MDR-TB) were limited and typically involved long treatment durations and high financial burdens. In the eastern European and central Asian (EECA) region, traditional inpatient tuberculosis (TB) care models, alongside...

Full description

Saved in:

Bibliographic Details
Published in:	BMJ global health Vol. 10; no. 11; p. e018099
Main Authors:	Allel, Kasim, Palmer, Tom, Abou Jaoude, Gerard Joseph, Korotych, Oleksandr, Yedilbayev, Askar, Vilc, Valentina, Corloteanu, Andrei, Macari, Mariana, Evghenia, Cula, Laticevschi, Dumitru, Shakhimurat-Shaimovich, Ismailov, Anar-Saduakasovna, Rakisheva, Gulzhan-Elbrusovna, Tulepova, Anatolievna-Ryazanet, Daria, Shahrizada-Yergalymovna, Aimbekova, Yatskevich, Natalia, Skrahina, Alena, Zhurkin, Dmitry, Avaliani, Zaza, Kiria, Nana, Lomtadze, Nino, Kiria, Nino, Avaliani, Teona, Khonelidze, Irma, Danelia, Maka, Maxim, Corina, Haghparast-Bidgoli, Hassan, Skordis, Jolene
Format:	Journal Article
Language:	English
Published:	England BMJ Publishing Group Ltd 08.11.2025 BMJ Publishing Group
Subjects:	Administration, Oral Adult Antitubercular Agents - administration & dosage Antitubercular Agents - economics Antitubercular Agents - therapeutic use Cost-Benefit Analysis Female Georgia (Republic) Health economics Humans Kazakhstan Male Middle Aged Moldova Original research Quality-Adjusted Life Years Republic of Belarus Rifampin - administration & dosage Rifampin - therapeutic use Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - economics Republic of Belarus Moldova Georgia (Republic) Kazakhstan Health economics Tuberculosis
ISSN:	2059-7908, 2059-7908
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!